In Vitro and in Vivo Studies on Two-Step Alkali-Fluoride-Treated Mg–Zn–Y–Nd Alloy for Vascular Stent Application: Enhancement in Corrosion Resistance and Biocompatibility

2019 ◽  
Vol 5 (7) ◽  
pp. 3279-3292 ◽  
Author(s):  
Pei Wang ◽  
Jing Liu ◽  
Shi Shen ◽  
Qiyao Li ◽  
Xujiang Luo ◽  
...  
2018 ◽  
Vol 16 (3) ◽  
pp. 126-136 ◽  
Author(s):  
Preeti Makkar ◽  
Swapan Kumar Sarkar ◽  
Andrew R. Padalhin ◽  
Byoung-Gi Moon ◽  
Young Seon Lee ◽  
...  

Background: Magnesium (Mg)-based alloys are considered to be promising materials for implant application due to their excellent biocompatibility, biodegradability, and mechanical properties close to bone. However, low corrosion resistance and fast degradation are limiting their application. Mg–Ca alloys have huge potential owing to a similar density to bone, good corrosion resistance, and as Mg is essential for Ca incorporation into bone. The objective of the present work is to determine the in vitro degradation and in vivo performance of binary Mg– xCa alloy ( x = 0.5 or 5.0 wt%) to assess its usability for degradable implant applications. Methods: Microstructural evolutions for Mg– xCa alloys were characterized by optical, SEM, EDX, and XRD. In vitro degradation tests were conducted via immersion test in phosphate buffer saline solution. In vivo performance in terms of interface, biocompatibility, and biodegradability of Mg– xCa alloys was examined by implanting samples into rabbit femoral condyle for 2 and 4 weeks. Results: Microstructural results showed the enhancement in intermetallic Mg2Ca phase with increase in Ca content. Immersion tests revealed that the dissolution rate varies linearly, with Ca content exhibiting more hydrogen gas evolution, increased pH, and higher degradation for Mg–5.0Ca alloy. In vivo studies showed good biocompatibility with enhanced bone formation for Mg–0.5Ca after 4 weeks of implantation compared with Mg–5.0Ca alloy. Higher initial corrosion rate with prolonged inflammation and rapid degradation was noticed in Mg–5.0Ca compared with Mg–0.5Ca alloy. Conclusions: The results suggest that Mg–0.5Ca alloy could be used as a temporary biodegradable implant material for clinical applications owing to its controlled in vivo degradation, reduced inflammation, and high bone-formation capability.


2010 ◽  
Vol 55 (10) ◽  
pp. A216.E2044
Author(s):  
Masayuki Tsuchida ◽  
Masa-aki Kawashiri ◽  
Hayato Tada ◽  
Chiaki Nakanishi ◽  
Katsuharu Uchiyama ◽  
...  

2001 ◽  
Vol 5 (8) ◽  
pp. 645-651
Author(s):  
M. Peeva ◽  
M. Shopova ◽  
U. Michelsen ◽  
D. Wöhrle ◽  
G. Petrov ◽  
...  
Keyword(s):  

2005 ◽  
Vol 25 (1_suppl) ◽  
pp. S198-S198
Author(s):  
Joseph R Meno ◽  
Thien-son K Nguyen ◽  
Elise M Jensen ◽  
G Alexander West ◽  
Leonid Groysman ◽  
...  

1994 ◽  
Vol 72 (06) ◽  
pp. 942-946 ◽  
Author(s):  
Raffaele Landolfi ◽  
Erica De Candia ◽  
Bianca Rocca ◽  
Giovanni Ciabattoni ◽  
Armando Antinori ◽  
...  

SummarySeveral “in vitro” and “in vivo” studies indicate that heparin administration may affect platelet function. In this study we investigated the effects of prophylactic heparin on thromboxane (Tx)A2 biosynthesis “in vivo”, as assessed by the urinary excretion of major enzymatic metabolites 11-dehydro-TxB2 and 2,3-dinor-TxB2. Twenty-four patients who were candidates for cholecystectomy because of uncomplicated lithiasis were randomly assigned to receive placebo, unfractionated heparin, low molecular weight heparin or unfractionaed heparin plus 100 mg aspirin. Measurements of daily excretion of Tx metabolites were performed before and during the treatment. In the groups assigned to placebo and to low molecular weight heparin there was no statistically significant modification of Tx metabolite excretion while patients receiving unfractionated heparin had a significant increase of both metabolites (11-dehydro-TxB2: 3844 ± 1388 vs 2092 ±777, p <0.05; 2,3-dinor-TxB2: 2737 ± 808 vs 1535 ± 771 pg/mg creatinine, p <0.05). In patients randomized to receive low-dose aspirin plus unfractionated heparin the excretion of the two metabolites was largely suppressed thus suggesting that platelets are the primary source of enhanced thromboxane biosynthesis associated with heparin administration. These data indicate that unfractionated heparin causes platelet activation “in vivo” and suggest that the use of low molecular weight heparin may avoid this complication.


2020 ◽  
Vol 72 (5) ◽  
Author(s):  
Mario Fadin ◽  
Maria C. Nicoletti ◽  
Marzia Pellizzato ◽  
Manuela Accardi ◽  
Maria G. Baietti ◽  
...  
Keyword(s):  

Sign in / Sign up

Export Citation Format

Share Document